Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
15.738 / 17.032
#125899

Re: Farmas USA

Framus, más vidas aún de TGTX !! Por fin, 5 años con ella
LOL

TG Therapeutics soars 23% on positive ublituximab data in multiple sclerosis

Dec. 10, 2020 7:31 AM ETTG Therapeutics, Inc. (TGTX)By: Mamta Mayani, SA News Editor4 Comments
  • TG Therapeutics (NASDAQ:TGTX) jumps 23% premarket on positive topline resultsfrom two global, Phase 3 studies, called ULTIMATE I & ULTIMATE II, evaluating ublituximab, an investigational, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS).
  • The ULTIMATE I & II trials enrolled a total of 1,094 patients. Both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial).
  • Ublituximab resulted in an ARR of <0.10 in each of ULTIMATE studies, with a relative reduction in ARR of ~60% and 50%, respectively, over teriflunomide.
  • Further analyses of both the studies including safety and secondary endpoints will be presented at an upcoming medical congress, targeted in H1 2021.
  • Additionally, data from these studies are intended to support a BLA submission for ublituximab in RMS targeted in mid-year 2021.
  • The company will host a conference call today at 8:30 AM ET to discuss the ULTIMATE I & II topline results.
#125900

Re: Farmas USA

Gilead Sciences to Acquire MYR GmbH
#125902

Re: Farmas USA

KPTI
Muchas gracias, tengo orden de compra en 15.00.
#125904

Re: Farmas USA

Este va a ser el siguiente ROR1 que se va a vender 
Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?